临床与病理杂志2024，Vol.44Issue(11)：1516-1526,11.DOI:10.11817/j.issn.2095-6959.2024.240665
TP53和KRAS基因在非小细胞肺癌免疫治疗中的预后意义
Prognostic significance of TP53 and KRAS genes in immunotherapy for non-small cell lung cancer
摘要
Abstract
Objective:Non-small cell lung cancer(NSCLC)is a common type of lung cancer.Immunotherapy has emerged as a key treatment strategy for advanced NSCLC,revolutionizing clinical management.However,some patients do not respond optimally to immunotherapy,potentially due to the genetic mutation status of the tumor.This study aims to explore whether TP53 and Kirsten rat sarcoma viral oncogene homolog(KRAS)gene statuses can serve as potential prognostic indicators for NSCLC patients undergoing immunotherapy. Methods:This retrospective study included 87 NSCLC patients with confirmed TP53 and KRAS gene statuses who received immunotherapy at the Affiliated Cancer Hospital of Zhengzhou University from January 2019 to June 2021.The mutation status of TP53/KRAS genes and patient survival outcomes were analyzed to evaluate their association with immunotherapy efficacy. Results:Compared with patients with wild-type TP53/KRAS genes,those with mutations in either TP53 or KRAS had a significantly higher likelihood of benefiting from immunotherapy(P<0.05).Additionally,patients with a single mutation in TP53 or KRAS exhibited a longer progression-free survival compared to those with concurrent TP53 and KRAS mutations(P<0.05). Conclusion:NSCLC patients with a single mutation in TP53 or KRAS may have a better prognosis when undergoing immunotherapy.关键词
非小细胞肺癌/免疫治疗/基因突变/TP53基因/KRAS基因Key words
non-small cell lung cancer/immunotherapy/gene mutation/TP53 gene/KRAS gene引用本文复制引用
李想,郭永军..TP53和KRAS基因在非小细胞肺癌免疫治疗中的预后意义[J].临床与病理杂志,2024,44(11):1516-1526,11.基金项目
河南省重大科技专项(201300310400).This work was supported by the Major Science and Technology Project of Henan Province,China(201300310400). （201300310400）
